SEC Form 4 · accession 0001209191-16-098806
CELGENE CORP /DE/ · CELG
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jacqualyn A Fouse
Officer — see remarks
Period of report
Feb 12, 2016
Accepted (ET)
Feb 16, 2016 · 5:00 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000816284
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Feb 12, 2016 | A | 29,219 | $0.00 | A | 87,315 | D | |
| Common Stock | Feb 12, 2016 | F | 13,746 | $102.45 | D | 73,569 | D | |
| Common Stock | holding | — | — | — | 1,313 | I | 401(k) Plan |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Represents shares of common stock relating to the 2013-2015 Long Term Incentive Plan and issued under the Celgene Corporation 2008 Stock Incentive Plan (Amended and Restated as of April 15, 2015).
Remarks
President Hematology and Oncology